SHetA2 Therapy
Why in News?
SHetA2 Therapy is in the news because the Indian Council of Medical Research (ICMR) officially validated and licensed this first-in-class oral drug candidate to Emcure Pharmaceuticals.
About SHetA2 Therapy
- What it is: SHetA2 is a chemically manufactured, low-molecular-weight small molecule therapy designed to be easily absorbed by the body.
- The Formulation: It is currently being evaluated as a cost-effective, take-home oral capsule or vaginal suppository.
- Primary Target: It specifically targets Cervical Intraepithelial Neoplasia (CIN)—the abnormal, precancerous cell changes caused by persistent high-risk Human Papillomavirus (HPV) infections.
- Therapy vs. Vaccine: Unlike preventive HPV vaccines, SHetA2 is purely therapeutic and intended for women who already have developed precancerous lesions. It does not prevent initial HPV infection.
- Alternative to Surgery: If successful, it will replace current invasive, ablative surgeries like Loop Electrosurgical Excision Procedure (LEEP), preserving healthy cervical tissue and protecting future pregnancy outcomes.
How it Works?
- Proteins Targeted: The drug selectively targets three host cell chaperone proteins: mortalin, Hsc70, and Grp78.
- Disrupting the Virus: It breaks the protective bond between these host proteins and the virus's cancer-causing E7 oncoprotein.
- Cell Death Induction: Stripped of its host protection, the viral E7 protein is destroyed, restoring tumour suppressor proteins (p53 and Rb) to trigger programmed cell death (apoptosis) in abnormal cells.
- Zero Systemic Toxicity: Preclinical and Phase I trials demonstrate that the therapy selectively kills tumour cells while completely sparing healthy tissues without major side effects.
Recent Status & Development
- Joint Partnership: The molecule is the result of an international collaboration between scientists at ICMR-NICPR (India) and the University of Oklahoma’s Stephenson Cancer Center (USA).
- Recent Stage: While Phase I safety trials have been conducted in the US for advanced solid tumours, the drug is still years away from routine clinical use until extensive efficacy trials are completed by Emcure.
